±«ÓãÖ±²¥

News

MRC/PMAC chair awarded to Dr Serge Gauthier

Published: 24 March 1997

On June 1, 1997, having spent ten years as director of the ±«ÓãÖ±²¥ Centre for Studies in Aging, Dr Serge Gauthier, Professor in the ±«ÓãÖ±²¥ Departments of Neurology and Neurosurgery, Psychiatry, and Medicine, will step down to become a Medical Research Council/Pharmaceutical Manufacturers Association of Canada (MRC/MPAC) researcher. This five-year research Chair is awarded to Dr Gauthier in recognition of his work on AlzheimerÂ’s disease. Thanks to the MRC/MPAC Chair -- which is also supported by Pfizer Canada and Hoescht Marion Roussel -- Dr Gauthier will be able to accelerate the pace of clinical research on AlzheimerÂ’s Disease by working in the following areas:

  • the prevention of AlzheimerÂ’s disease in people at risk;
  • the safest and most efficient use of drugs which are soon to be approved and made available by general prescription for the symptomatic treatment of early to intermediate stages of AlzheimerÂ’s disease;
  • the symptomatic treatment of intermediate and later stages of AlzheimerÂ’s disease with single or combination drugs therapies; and
  • the symptomatic treatment of Lewy body dementia -- a combination of AlzheimerÂ’s and ParkinsonÂ’s diseases.

Editor of Clinical Diagnosis and Management of AlzheimerÂ’s Disease (April 1996, Martin Dunitz Publisher, London) which quickly became after its release a major reference manual, Dr Gauthier is also planning educational programs for physicians and other health professionals interested in the diagnosis and treatment of AlzheimerÂ’s disease. Together with Drs A. Burns and W. Petit, Dr. Gauthier is the co-author of AlzheimerÂ’s Disease in Primary Care, a pocketbook commissioned by Pfizer International and now available for medical teaching.

Dr Gauthier intends to remain an active member of the ±«ÓãÖ±²¥ Centre for Studies in Aging and he is looking ±«ÓãÖ±²¥ to a very productive five-year term dedicated to the advancement of physiciansÂ’ education in AlzheimerÂ’s disease and the optimal use of AlzheimerÂ’s-specific drug treatments.

Back to top